In the early 1960s at the National Institutes of Health in Washington, D.C., Maxine Singer used a specialized enzyme to assemble synthetic RNA molecules from adenine, guanine, cytosine, and uracil. Singer had graduated from Swarthmore College in 1952, where she switched her major from chemistry to biology, before earning her biochemistry doctorate from Yale University in 1957. Advised by her Yale professor that the future of biochemistry lay in nucleic acids, she joined Leon Heppel’s laboratory at the National Institutes of Health as a postdoctoral fellow. Working alongside Heppel and Marshall Nirenberg, Singer synthesized precise RNA sequences to determine how cells read genetic instructions.
Synthesizing the Genetic Dictionary
By assembling RNA sequences with predetermined base combinations, the research team tested which amino acids were linked together in response. According to a biography published by the Science History Institute, they matched each amino acid to a specific triplet of RNA bases, compiling the chemical dictionary of three-letter codons that dictates protein synthesis. Singer's technical skill in enzymatic synthesis provided the exact physical material needed to solve the code. Though she initially planned a short stay at the National Institutes of Health, her postdoctoral appointment turned into a permanent research role where she remained until 1979.
Confronting the Unknowns of Recombinant DNA
When recombinant DNA techniques began taking shape around 1970, enabling researchers to combine genetic material from different organisms, Singer recognized that rapid experimental progress presented unquantified hazards. Co-organizing the 1973 Gordon Research Conference, she led a formal debate on the public health and biological risks associated with recombinant research. Recognizing that safety concerns required broader institutional review, Singer co-authored a letter published in Science later in 1973. The letter urged the National Academy of Sciences to investigate potential risks associated with recombinant DNA technology and establish research oversight.
The Asilomar Mandate and Self-Regulation
Singer’s petition contributed directly to the convening of the 1975 International Conference on Recombinant DNA Molecules, known as the Asilomar Conference. As a co-organizer of the meeting, Singer ensured the debate extended beyond laboratory scientists by forming a dedicated legal panel to address public policy and legal oversight. The conference established consensus standards for laboratory containment and risk management. Following the conference, Singer assisted the National Institutes of Health in formulating official safety guidelines that governed genetic engineering research practice across the United States.
Uncovering Transpositions in Mammalian Genomes
Singer later moved to the National Cancer Institute, where she headed the Laboratory of Biochemistry during the 1980s. Her research examined repetitive DNA sequences scattered across mammalian genomes, specifically long interspersed nucleotide elements, or LINEs. Singer discovered the mechanism by which LINEs undergo transposition—moving from place to place on the genome—and proposed that these shifts contribute to genetic diseases, a hypothesis later confirmed by other scientists. In 1988, Singer became president of the Carnegie Institution, serving through 2002, and was later awarded the National Medal of Science for her research accomplishments and public leadership.
Singer’s career established a documented precedent that scientific discovery must be accompanied by structured self-evaluation and transparent governance. Her dual legacy—synthesizing the experimental RNA molecules that decoded the three-letter genetic code and organizing the early oversight of recombinant DNA—demonstrated that scientific innovation and institutional accountability can move forward in tandem.
AI-generated editorial illustration; not a documentary photograph.
Source: Maxine Singer
SIGNAL TITANS
Leave a Reply